By Fineline Cube 
GlaxoSmithKline plc (GSK, NYSE: GSK) has reported highly promising data from the global Phase I BEHOLD-1 clinical trial for its investigational antibody-drug conjugate (ADC), mocertatug rezetecan (Mo-Rez). The monotherapy demonstrated a confirmed objective response rate (cORR) of 62% in patients with platinum-resistant ovarian cancer (PROC) and 67% in those with recurrent or advanced endometrial cancer (EC), two gynecological malignancies with significant unmet medical need.
Clinical Data Snapshot
| Indication | Dose Cohort | Confirmed ORR (cORR) | Patients (Responders/Total) | 95% CI |
|---|---|---|---|---|
| Platinum-Resistant Ovarian Cancer (PROC) | 5.8 mg/kg | 62% | 21/34 | 44%, 78% |
| Recurrent/Advanced Endometrial Cancer (EC) | 4.8 mg/kg | 67% | 8/12 | 35%, 90% |
| Total Trial Enrollment (as of cutoff) | 224 patients |
Drug Profile & Partnership
- Molecule: Mocertatug rezetecan (Mo-Rez), a novel B7-H4-targeting ADC.
- Structure: Fully human anti-B7-H4 monoclonal antibody linked to a topoisomerase inhibitor payload (DAR of 6).
- Target Rationale: B7-H4 is a tumor-associated antigen highly expressed in various solid tumors, including ovarian and endometrial cancers, with limited expression in healthy tissues, making it an attractive target.
- Global Rights: GSK holds exclusive global development and commercialization rights (excluding Greater China) from Hansoh Pharmaceutical Group Co., Ltd. (HKEX: 3692), the originator of the asset.
Safety Profile (Highest Phase Ib Dose)
- PROC Patients: Most common AEs were nausea (86%), neutropenia (73%), anemia (52%), fatigue (52%), and alopecia (52%).
- EC Patients: Most common AEs were nausea (79%), neutropenia (58%), anemia (54%), vomiting (46%), and fatigue (42%).
- The safety profile was deemed manageable and consistent with the mechanism of action of a topoisomerase inhibitor-based ADC.
Strategic Implications
- High Unmet Need: The robust response rates in heavily pre-treated PROC and EC patients position Mo-Rez as a potential best-in-class therapy in these difficult-to-treat settings.
- ADC Portfolio Expansion: This data significantly de-risks Mo-Rez and bolsters GSK’s growing and highly competitive oncology ADC pipeline.
- Path to Registration: The ongoing dose-expansion phase of BEHOLD-1 is expected to provide the pivotal data package needed for potential accelerated regulatory submissions.
- Market Opportunity: Successful approval would grant GSK access to large, global markets for ovarian and endometrial cancer therapies, where effective later-line options are scarce.
Forward-Looking Statements
This brief is based on interim data from an ongoing Phase I trial. The safety and efficacy of mocertatug rezetecan have not been fully established. Future development is subject to further clinical data, regulatory review, and the risks inherent in drug development. There can be no assurance of marketing approval.-Fineline Info & Tech